Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 64, Issue 3, pp 601–605 | Cite as

The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck

  • Kazim Uygun
  • Ahmet BiliciEmail author
  • Hakan Karagol
  • Murat Caloglu
  • Irfan Cicin
  • Gorkem Aksu
  • Merdan Fayda
  • Sernaz Uzunoglu
Original Article

Abstract

Purpose

Several studies have shown that the concurrent administration of chemotherapy (CHT) and radiotherapy (RT) is superior to RT alone in patients with inoperable non-metastatic squamous cell carcinoma of the head and neck (InSCCHN). We compared the efficacy and safety profile of RT and concurrent cisplatin CHT given in two different schedules to patients with previously untreated InSCCHN.

Methods

Fifty patients with previously untreated InSCCHN admitted to our oncology department were included in the study. Thirty of 50 (60%) patients with a younger age or good performance status (PS) (ECOG 0-1) received cisplatin 100 mg/m2 on a 21-day schedule (group A). Other 20 (40%) patients with older age or poor PS (ECOG 2) received cisplatin 40 mg/m2 on a 7-day schedule (group B). Each of the 50 patients received concurrent conventional dose RT according to primer tumor location.

Results

The median follow-up is 12 months for group A and 12.5 months for group B. Twenty-eight (93.3%) patients in group A and 18 (90%) in group B were evaluable for response. The complete response rate was 50% in group A and 40% in group B (P > 0.05). The objective response rate was 92% in group A and 90% in group B (P > 0.05). All grade 3–4 toxic events were seen in 16 (53.3%) of group A patients and 8 (40%) of group B patients (P > 0.05).

Conclusions

Comparison between two treatment modalities appears to result in statistically similar response rates and adverse event profile. A randomized phase III trial is required to confirm the safety and efficacy of weekly cisplatin therapy in patients with poor PS and/or older age at diagnosis.

Keywords

Inoperable head and neck cancer Squamous cell Weekly cisplatin Three weekly Cisplatin Concurrent chemoradiotherapy 

Notes

Acknowledgments

This study was presented in ESMO 2006, in a poster session. K. Uygun, H. Karagol, M. Caloglu, I. Cicin, V. Caloglu, S. Uzunoglu, P. Saip. The Comparison of Weekly Cisplatin Chemotherapy Concurrent with Radiotherapy in Patients with Previously Untreated Inoperable Non-Metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2006 (abstr 585).

References

  1. 1.
    Bernier J, Bentzen SM (2003) Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 39:560–571PubMedCrossRefGoogle Scholar
  2. 2.
    Beckman GK, Hoppe F, Pfreundner L, Flentje MP (2005) Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27:36–43CrossRefGoogle Scholar
  3. 3.
    Million RR, Cassisi NJ (1994) Management of head and neck cancer: a multidisciplinary approach. JB Lippincott, PhiladelphiaGoogle Scholar
  4. 4.
    Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98PubMedCrossRefGoogle Scholar
  5. 5.
    Pignon JP, Baujat B, Bourhis J (2005) Individual patient data meta-analyses in head and neck carcinoma: what have we learnt? Cancer Radiother 9:31–36PubMedGoogle Scholar
  6. 6.
    Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M (1995) The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol 35:91–99CrossRefGoogle Scholar
  7. 7.
    Bernier J, Bentzen SM (2003) Head and neck cancer management: which postoperative treatment best serves your patient? In: 29th Annual meeting, American Society of Clinical Oncology, Educational Book, pp 306–312Google Scholar
  8. 8.
    Medina JA, Rueda A, de Pasos AS, Contreras J, Cobo M, Moreno P, Benavides M, Villanueva A, Alba E (2006) A phase II study of concomitant boast radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 79:34–38PubMedCrossRefGoogle Scholar
  9. 9.
    Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Iyer S, Kuriakose MA (2006) Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Can Res Ther 2:100–104CrossRefGoogle Scholar
  10. 10.
    Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458–1464PubMedGoogle Scholar
  11. 11.
    Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, al Sarraf M, Mowry PA, Curran W, Crissman J, Rodríguez M, Vélez-García E (1990) Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of head and neck. Long-term results of the Radiation Therapy Oncology Group study 81–17. Cancer 66:1861–1868PubMedCrossRefGoogle Scholar
  12. 12.
    Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
  13. 13.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  14. 14.
    Cox JD, Stetz JA, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedGoogle Scholar
  15. 15.
    Stephard DA (1976) The 1975 declaration of Helsinki and consent. Can Med Assoc J 115:1191–1192Google Scholar
  16. 16.
    Glickman AS, Slotman G, Doolittle C 3rd, Clark J, Koness J, Coachman N, Posner M, DeRosa E, Wanebo H (1994) Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 30:1043–1050Google Scholar
  17. 17.
    Serin M, Erkal HS, Cakmak A (1999) Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol 38:1031–1035PubMedCrossRefGoogle Scholar
  18. 18.
    Byfield JE, Sharp TR, Frankel SS, Tang SG, Callipari FB (1984) Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 2:406–413PubMedGoogle Scholar
  19. 19.
    Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard RT in locally advanced head and neck cancer. J Clin Oncol 12:2648–2653PubMedGoogle Scholar
  20. 20.
    Gupta NK, Pointon RC, Wilkinson PM (1987) A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 38:575–581PubMedCrossRefGoogle Scholar
  21. 21.
    Haffty BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli AC, Fischer JJ (1997) Chemotherapy as an adjunct to radiation therapy in the treatment of squamous cell carcinoma of head and neck: results of the Yale mitomycin C randomized trials. J Clin Oncol 15:268–276PubMedGoogle Scholar
  22. 22.
    Barzan L, Veronesi A, Caruso G, Serraino D, Magri D, Zagonel V, Tirelli U, Comoretto R, Monfardini S (1990) Head and neck cancer and ageing: a retrospective study in 438 patients. J Laryngol Otol 104:634–640PubMedGoogle Scholar
  23. 23.
    Dreyfuss AI, Clark JR (1991) Analysis of prognostic factors in squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 5:701–712PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Kazim Uygun
    • 1
  • Ahmet Bilici
    • 2
    • 6
    Email author
  • Hakan Karagol
    • 3
  • Murat Caloglu
    • 4
  • Irfan Cicin
    • 3
  • Gorkem Aksu
    • 5
  • Merdan Fayda
    • 5
  • Sernaz Uzunoglu
    • 3
  1. 1.Department of Medical Oncology, Medical FacultyKocaeli UniversityKocaeliTurkey
  2. 2.Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research HospitalIstanbulTurkey
  3. 3.Department of Medical Oncology, Medical FacultyTrakya UniversityEdirneTurkey
  4. 4.Department of Radiation Oncology, Medical FacultyTrakya UniversityEdirneTurkey
  5. 5.Department of Radiation Oncology, Medical FacultyKocaeli UniversityKocaeliTurkey
  6. 6.IstanbulTurkey

Personalised recommendations